Building on the recently completed and ongoing clinical trials of Akt and AR inhibition in prostate cancer, we have begun to define the mechanisms of response and resistance to Akt inhibition with the goal of optimizing patient selection and developing combinatorial and sequential therapeutic strategies to maximize response and overcome resistance. The gene discussed is AR; the disease is prostate carcinoma.